The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 26784936 |
2 |
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid. |
Catabasis Pharmaceuticals |
| 24864041 |
16 |
Synthesis and evaluation of (E)-2-(acrylamido)cyclohex-1-enecarboxylic acid derivatives as HCA1, HCA2, and HCA3 receptor agonists. |
Latvian Institute of Organic Synthesis |
| 24900524 |
39 |
Identification of Hydroxybenzoic Acids as Selective Lactate Receptor (GPR81) Agonists with Antilipolytic Effects. |
TBA |
| 22435740 |
43 |
(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans. |
Arena Pharmaceuticals |
| 24900372 |
60 |
Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. |
TBA |
| 19592242 |
29 |
Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia. |
Merck Research Laboratories |
| 19307116 |
52 |
GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a. |
Merck Research Laboratories |
| 17452318 |
9 |
Nicotinic acid receptor agonists differentially activate downstream effectors. |
Arena Pharmaceuticals |
| 22209457 |
47 |
SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist. |
Merck Research Laboratory |
| 21615150 |
14 |
Progress in structure based drug design for G protein-coupled receptors. |
Heptares Therapeutics |
| 21185185 |
43 |
The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties. |
Merck Research Laboratories |
| 21167710 |
18 |
Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A). |
Leiden University |
| 24900295 |
61 |
Discovery of a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia |
TBA |
| 20813948 |
63 |
Spiroindolones, a potent compound class for the treatment of malaria. |
Swiss Tropical and Public Health Institute |
| 20724150 |
51 |
Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity. |
F. Hoffmann-La Roche |
| 20615702 |
28 |
GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. |
Merck Research Laboratories |
| 20452209 |
64 |
Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A. |
Merck Research Laboratories |
| 20444602 |
66 |
Anthranilic acid replacements in a niacin receptor agonist. |
Merck |
| 20363624 |
20 |
Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a). |
Arena Pharmaceuticals |
| 20184326 |
40 |
Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate. |
Merck Research Laboratories |
| 19524438 |
38 |
5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b. |
Arena Pharmaceuticals |
| 19309152 |
81 |
Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats. |
Merck Research Laboratories |
| 18983141 |
11 |
Nicotinic acid receptor agonists. |
Arena Pharmaceuticals |
| 18760600 |
14 |
Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. |
Merck Research Laboratories |
| 18752940 |
22 |
Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A. |
Merck Research Laboratories |
| 18665582 |
12 |
3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. |
Arena Pharmaceuticals |
| 18029181 |
38 |
Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A. |
Merck Research Laboratories |
| 17931863 |
2 |
3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b. |
Arena Pharmaceuticals |
| 17804224 |
64 |
Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a. |
Arena Pharmaceuticals |
| 17588745 |
41 |
Agonist lead identification for the high affinity niacin receptor GPR109a. |
Arena Pharmaceuticals |
| 17358052 |
64 |
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. |
Arena Pharmaceuticals |
| 32199732 |
48 |
Discovery of novel pyrrole derivatives as potent agonists for the niacin receptor GPR109A. |
Daiichi Sankyo |
| 31932225 |
74 |
Identification of novel GPR81 agonist lead series for target biology evaluation. |
Astrazeneca |
| 29939744 |
179 |
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential. |
Shanghaitech University |
| 25737085 |
26 |
Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists. |
Leiden University |
| 29709786 |
18 |
Discovery of coumarin-dihydroquinazolinone analogs as niacin receptor 1 agonist with in-vivo anti-obesity efficacy. |
Csir-Central Drug Research Institute |
| 28668361 |
48 |
Synthesis and evaluation of (E)-2-(5-phenylpent-2-en-4-ynamido)cyclohex-1-ene-1-carboxylate derivatives as HCA2 receptor agonists. |
Latvian Institute of Organic Synthesis |
Search and Browse
